Member Info for 1DayRodney

Interesting....

Re recent RNS:

'The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A'

May be if the BOD could demonstrate this, say, through an online live Q&A presentation, the shareholders might have more confidence and faith in the BOD, but alas I think this will not happen.

Been here over 5 yrs (back when we only had 38M shares in circ!). I agree with NUG, Gino is an excellent and seemingly enthusiastic CSO.

The products and the science behind them is fantastic but the finances are in a pitiful state. I would like to see more financial/salary reduction, maybe in lieu of options from the BOD and show it's not just the LTHs bearing the load.

Amers quote:

'I think shares have already been given to those who are likely to votes yes. Allocation doesn't depends on the out of the GM of the 15th'.

With reference to the RNS released 29 Sept...

''The Conditional Placing and the Retail Offer are still conditional on, inter alia, the passing of resolutions 1 and 2 at the General Meeting (expected to be convened for 15 October 2025'

This is part of the note sent by my broker after I received notice of my allocation...

"The new shares are due to be credited to your Account shortly before 8am on 16 October 2025. However, this may be delayed in the event the company does not deliver your shares to us by this time. Please note admission is subject to the approval of a resolution at the General Meeting expected to be convened on Wednesday 15 October."

Currently the transaction is marked a pending.

Is some able to positively confirm if that 12M deal was buy or a sale , thanks.

I'm with HL and they informed me of my allocation on Monday. They've also reserved the cash amount and marked as a 'pending order'.

Why are certain posters so morbidly obsessed with a takeover or administration?

I'd like to know why we seem to be at the mercy of the NHS/NICE for (apparently) this company's survival?

Both current assay derivatives of the Genedrive device are groundbreaking and certified for other areas/international/European sales. I know everyone is fixated with US sales but why are we not selling elsewhere in the meantime? The original PALOH study and MT-RNR1 CE-IVD/Uk certs were years ago!

What's the point of a 'sales team' (or indeed a non-executive director who specialises in commercialisation/sales - Tom Lindsay) if we're just twiddling our thumbs waiting for NICE and the NHS to decide our fate? What's blocking us selling elsewhere?

This delay in 👍🏻or👎🏻, the (seemingly) perpetual 'results gathering' and continual shareholder dilution is destroying the confidence in what could be an headlining company.

I've (unfortunately) been a holder for many years and find it hugely frustrating at the lack of sales throughout.

I did vote 'yes' to the latest notice -🤞🏻this company's fortune can be turned around!

# separate vote for each account

predictive text 🙄

For Hargreaves Lansdowne:

Log on to your account through the webpage(not the app).

This will open your 'accounts and dealing' page.

On the right side of the page there are various headed boxes. Select the link on the one titled 'Shareholder Meetings'

This will take you to a page which will list any available meetings/votes for your holdings and the vote cut-off date.

Select 'Give Instruction' next to the appropriate company name. This will take you s separate website where you can read the resolutions and place your vote - for/against/abstain.

If you have the same holding in more than one account e.g. you hold Genedrive in a SIPP and a trading account, then you get to cast a separate bite for each account.

When you go vack to the 'Shareholder Meetings' page, it will now show 'instruction given' next to the company name.

HTH

Personally, I think this whole situation that could have probably been avoided if the company or their representatives were more communicative, be it through RNS or presentations.

In my opinion, this has lead to confused speculation, misinformation (deliberate or otherwise) and frustrated shareholders trying to source potentially misleading information from 3rd parties.

Unfortunately this action/reaction is likely detrimental to everybody.

The seemingly endless acceptance trials, testing, persistent bureaucracy, fruitless promises of overseas sales and shrinking stock value is hugely trying but even an little company interaction could probably have prevented some of this.

@GMkt

I believe the GDR kit is also authorised to be used in/by a lab as well 'at the bedside' use.

It would be a rapid and very cost effective method for a lab to carry out a compulsory test like this.

Also, because it uses saliva as the sample, the collection of the sample will be quick and can carried out by competent but less qualified staff than say, a current blood sample would be.

It could also even raise the prospect of a patient taking the swab sample themselves at home and posting it in like some stool and urine samples are done now. Especially as people are now used to swab sampling after using over-the-counter Covid tests recently.

@stephen11 or anyone else with HL

For those who don't know how to but wish to vote at the AGM and you are with Hargreaves Lansdowne, you can vote by logging into your account through the webpage (not the app).

On your account's front page you'll see a section on the right-hand site labelled "Shareholder Meetings", click there and it take you to a list of any meetings available.

Note - if you hold shares in more than one account, you'll get to vote with the shares held in each account e.g. if you hold shares in a dealing account and a pension, you get to vote twice.

HTH

EmeraldCarrot wrote

"Likely the long term shareholders invested way too early."

Ha,ha this type of statement always makes me laugh wherever I see it.

Perfect 20/20 hindsight investor/trader - having all the clarity of the past without having to make any decisions about the future! lol.

## "forming a concert party or to individually make an"

Where did I state we had an institutional investor?

You seem rather frantic EC.

"a couple of major shareholders". As you say, where's the TR-1 for these imaginary major shareholders you talk of? No one is anywhere near the threshold (>30%) for either forming a concert party to make an offer/compulsory takeover offer.

Even all the shares owned by the board (approx 6.25m) only represents just over 1% of the issue.

Also, why do you keep starting a new thread every time you post ??🙄

I don't understand all this urgency and, quite frankly, ridiculous desperation to be bought out.

This company has absolutely massive potential growth, way past these weedy low pence speculations.

Certain (overly prolific) posters only seem to have eyes for a titchy trading profit. If you want to trade, then trade (+18% today if you're sharp!) but all this constant buyout speculation is becoming boring.

Sure, there'll probably be a need for further funding or investment in the meantime, but in a year's time, the sales figures will likely be transformational. Once in the bosom of the NHS, sales will enable the company to become self funding and enable external sales to fund further product/assay development and thus GDR will grow exponentially. We are debt free, owing to no one and are not under the yoke of an institutional investor.

Even I can see we may (eventually) capitulate, but it should be further down the line and for gold nuggets, not naffing peanuts!

🟩🥕EmCarrot wrote

"There is nothing stopping the hospitals from using the machine before the study is over."

There's nothing stopping any hospital using it now. NICE authorised it's use in the NHS in the conclusion of their study in March 2023 but any trust wishing to use it (unless they are part of the study) would need to fund it themselves.

Approval is Ben Nevis. USA sales are Everest i.e. worlds apart!

No doubt the stock price will move IF we get approval but a little less hype a little more reality needed me thinks....

Personally, I would say that talk of takeover is still too early. GDR are still a very high (financial) risk despite the relatively low company value.

There are probably thousands of mini-pharma type companies in the world at a similar stage as GDR for the picking.

Once NHS are regular customers for one or both current assays, we've received FDA approval(or very near it) and we have another assay in development, then BBP may have a proper look.

If we don't succeed financially, then BBP could just buy up the bones anyways.

We may well be courting but think we're still a little way off yet.

(all imo of course)